Adverum Biotechnologies, Inc.
ADVM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.06 | -0.03 | -0.01 |
| FCF Yield | -26.56% | -86.09% | -46.99% | -29.01% |
| EV / EBITDA | -3.59 | -1.95 | -2.92 | -3.21 |
| Quality | ||||
| ROIC | -140.51% | -62.67% | -40.25% | 38.93% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.59 | 0.79 | 0.91 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -34.75% | -34.75% | 999,900.00% |
| Free Cash Flow Growth | 27.34% | 9.55% | -51.86% | -32.63% |
| Safety | ||||
| Net Debt / EBITDA | -1.33 | -1.02 | -0.95 | -0.77 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,411.42 | -798.73 | -239.69 | -20.57 |